Tolcapone is worth a try when other treatments in patients with fluctuating Parkinson's disease fail or are inappropriate

Author： Adis International Limited

Publisher： Adis International

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.21, Iss.11, 2005-11, pp. : 1-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson's Disease

By Baas H.

Clinical Pharmacokinetics, Vol. 40, Iss. 5, 2001-01 ,pp. : 383-393

Adis International

Access to resources Recommend Favorite

Tolcapone: A Review of its Use in the Management of Parkinson's Disease

By Gillian M. Keating Katherine A. Lyseng-Williamson

CNS Drugs, Vol. 19, Iss. 2, 2005-01 ,pp. : 165-184

Adis International

Access to resources Recommend Favorite

By Borges N.

Drug Safety, Vol. 26, Iss. 11, 2003-01 ,pp. : 743-747

Adis International

Access to resources Recommend Favorite

Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy

By Borges Nuno

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 69-73

Informa Healthcare

Access to resources Recommend Favorite

Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson's Disease

By Gallagher David A. Schrag Anette

CNS Drugs, Vol. 22, Iss. 7, 2008-01 ,pp. : 563-586

Adis International

Access to resources Recommend Favorite